biotechnological medicines in development for prostate cancer
TRANSCRIPT
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
1/15
for prostate ca
Biotechnological medicin
in developm
Georgios LavasidisMedical student at the
University of Ioannina
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
2/15
Epidemiology
Prostate Cancer (C61): 2008 Estimates
European Age-Standardised Incidence Rates per 100,000 population, Males, EU27 Countries
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
3/15
Epidemiology
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
4/15
Cellular immunotherapy
Date of approval():
6/9/2013
sipuleucel-T
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
5/15
Medicines in development
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
6/15
Clinical trials: Phase/Ia
REIC (Reduced Expression inImmortalized Cells): tumorsuppressor gene
Forced gene expression usingadenoviral vector
REIC gene therapy
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
7/15
REIC gene therapy
Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous c
vaccination therapy (Review), Watanabe et al., Oncol Lett. Mar 2014; 7(3): 595
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
8/15
REIC gene therapy
Preclinical safety and efficacy of in situ REIC/Dkk-3 gene therapy for prostate
cancer, Kawauchi et al., Acta Med Okayama. 2012;66(1):7-16
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
9/15
Antisense RNAs: RNAs that bind to complementary m
inhibit their translation
LNA-based oligonucleotide that targets the androgen(AR)
The expression of AR is increased in some prostate cand is related to proliferation and survival of cancer
Androgen receptor antisense oligonucleo(EZN-4176)
LNA monomer: The bridge between the
2'-
and the 4'-C enhances the stabilityof the molecule
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
10/15
LNA
(AR Gene)
[Clinical tria
Androgen receptor antisense oligonucleo(EZN-4176)
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
11/15
(Control)
(Control)
Reduced expression of the androgen receptor by third generation of antisen
shows antitumor activity in models of prostate cancer, Zhang et al., Mol Can
Ther. 2011 Dec;10(12):2309-19
[Preclinical tria
Androgen receptor antisense oligonucleo(EZN-4176)
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
12/15
Clinical trials: Phase
Metastatic castration-resistant prostate Ca
Pox-viruses
PSA-TRICOM vaccine
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
13/15
PSA-TRICOM vaccine
Overall survival analysis of a phase II randomized controlled trial of a Poxvira
based PSA-targeted immunotherapy in metastatic castration-resistant prosta
cancer, Kantoff PW et al., J Clin Oncol. 2010 Mar 1;28(7):1099-105
Phase II RCT
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
14/15
Medicine Type Development st
anti-STEAP1 ADC mAb-drug conjugate Clinical trials: Ph
rilotumumab mAb Clinical trials: Ph
anti-integrin mAb mAb Clinical trials: Ph
ipilimumab mAb Clinical trials: Ph
nelipepmut-S peptide vaccine Clinical trials: Ph
BPX-101 dendritic cell vaccine Clinical trials: Ph
GVAX-PCa immunotherapeutic vaccine Clinical trials: Ph
TeloB-Vax telomerase cancer
vaccine
DNA vaccine Clinical trials: Ph
AdV-tk + valacyclovir gene therapy Clinical trials: Ph
Other possible medicines
-
7/24/2019 Biotechnological Medicines in Development for Prostate Cancer
15/15